Orr W C, Harnish M J
Lynn Institute for Healthcare Research, Oklahoma City, OK , USA.
Aliment Pharmacol Ther. 2003 Jun 15;17(12):1553-8. doi: 10.1046/j.1365-2036.2003.01594.x.
It has been presumed that nocturnal acid breakthrough may pose a risk for the development of nocturnal gastro-oesophageal reflux.
To investigate the occurrence of gastro-oesophageal reflux and acid breakthrough during polygraphically monitored sleep under conditions of powerful acid suppression with omeprazole 20 mg b.d. and an additional dose of ranitidine at bedtime.
Nineteen individuals with symptomatic gastro-oesophageal reflux disease were studied. Each individual was studied on two occasions subsequent to 1 week of 20 mg of omeprazole treatment b.d. Subjects underwent 24-h oesophageal and gastric pH recording, with polysomnographic monitoring. Participants received either 150 mg ranitidine at bedtime or placebo, prior to a provocative meal.
Ranitidine administration resulted in a significant (P < 0.01) reduction in the percentage of time the intragastric pH < 4.0. There was no significant difference with regard to measures of gastro-oesophageal reflux, and reflux events were not noted to occur with a significantly greater frequency during periods of nocturnal acid breakthrough compared with control intervals without acid breakthrough.
The administration of 150 mg ranitidine at bedtime did not significantly alter the occurrence of sleep-related gastro-oesophageal reflux.
据推测,夜间酸突破可能会增加夜间胃食管反流发生的风险。
在使用20毫克每日两次的奥美拉唑强力抑制胃酸,并在睡前额外加用一剂雷尼替丁的情况下,通过多导睡眠监测来研究胃食管反流和酸突破的发生情况。
对19名有症状的胃食管反流病患者进行研究。在每日两次服用20毫克奥美拉唑治疗1周后,对每位患者进行两次研究。受试者在进食刺激性食物前,接受24小时食管和胃pH值记录,并进行多导睡眠监测。参与者在睡前服用150毫克雷尼替丁或安慰剂。
服用雷尼替丁后,胃内pH值<4.0的时间百分比显著降低(P<0.01)。在胃食管反流的测量方面没有显著差异,并且与无酸突破的对照时间段相比,在夜间酸突破期间反流事件的发生频率没有显著增加。
睡前服用150毫克雷尼替丁不会显著改变与睡眠相关的胃食管反流的发生情况。